|Mr. Thomas K. Equels||Exec. Vice Chairman, CEO & Pres||N/A||N/A||1953|
|Mr. Adam Pascale||CFO & Chief Accounting Officer||282.88k||N/A||1948|
|Mr. Peter W. Rodino III, J.D.||Exec. Director of Gov.al Relations, Gen. Counsel & Sec.||381.16k||N/A||1951|
|Mr. Wayne S. Springate||Sr. VP of Operations||N/A||N/A||1971|
|Dr. David R. Strayer||Chief Scientific Officer & Medical Director||N/A||N/A||1946|
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Hemispherx Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.